https://www.selleckchem.com/products/cpi-1205.html
48, p less then 0.001) and higher non-relapse mortality (HR 2.68, p less then 0.001) than those without BSI. In conclusion, alloHCT patients with BSI had a higher risk of mortality than those who did not develop BSI. The inclusion of PTCy as part of GVHD prophylaxis was found to be an independent risk factor for BSI during early post-transplant follow-up. Single-center analyses focused on reporting incidence and risk factors for BSI highlight the need for active implementation of pre-emptive strategies to decrease BSI incidence in the
Like
Comment
Share
